Please login to the form below

Not currently logged in
Email:
Password:

Castleman

This page shows the latest Castleman news and features for those working in and with pharma, biotech and healthcare.

World Castleman Disease Day

World Castleman Disease Day

About Castleman disease. Castleman disease (CD) is the name given to a group of rare and life-threatening lymphoproliferative disorders that affect the lymph nodes and related tissues. ... One subtype of CD is idiopathic Multicentric Castleman Disease

Latest news

  • Roche snags pair of FDA breakthrough designations Roche snags pair of FDA breakthrough designations

    First launched in Japan for 2005 for Castleman's disease - and subsequently getting the green light for rheumatoid arthritis and systemic juvenile idiopathic arthritis in several markets including the US and

  • Roche wins early use RA approval for RoActemra in Europe Roche wins early use RA approval for RoActemra in Europe

    Adds to existing indications in arthritis and Castleman’s disease. Roche's arthritis brand RoActemra (tocilizumab) has widened its European licence, winning a new EU indication to treat early rheumatoid arthritis.

  • EC approves Janssen rare blood disorder drug EC approves Janssen rare blood disorder drug

    Sylvant available to treat multicentric Castleman's disease. Janssen's Sylvant this week became the first drug approved in Europe to treat the rare blood disorder multicentric Castleman's disease (MCD).

  • FDA approves Janssen drug for rare Castleman’s disease FDA approves Janssen drug for rare Castleman’s disease

    Sylvant approved to treat lymphoma-like condition. The US FDA has approved a new drug to treat a rare cancer-like condition known as multicentric Castleman's disease. ... It is also designated an orphan drug due to the rarity of multicentric Castleman's

  • EMA backs Janssen rare disease drug for approval EMA backs Janssen rare disease drug for approval

    Castleman's disease treatment Sylvant wins CHMP recommendation. J&J subsidiary Janssen-Cilag's Castleman's disease treatment Sylvant (situximab) has been recommended for approval in Europe. ... Castleman's disease is a rare disorder characterised by

More from news
Approximately 4 fully matching, plus 4 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

DATA shutterstock_1818502577-640.jpg
Empowering patients empowers results
Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials...
Don’t limit diversity to just representation in clinical trials
What is the power of diversity in the healthcare environment? Can it make clinical trials more inclusive?...
Oh no… not more training
Paul Hutchings, founder of fox&cat, discusses ways to help your team manage pressure in a more human, pressure-centric and engaging way...

Infographics